Anti-VEGF 165A antibody (ab106580)


  • Product nameAnti-VEGF 165A antibody
    See all VEGF 165A primary antibodies
  • Description
    Rabbit polyclonal to VEGF 165A
  • Specificityab106580 will recognize both native and recombinant Human VEGF 165A in cell supernatants and certain body fluids. The immunogen is full length recombinant human VEGF-165 protein, but this has high homology with multiple VEGF isoforms, therefore it should recognise these other isoforms too.
  • Tested applicationsSuitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length protein corresponding to Human VEGF 165A.
    Database link: P15692-4

  • Positive control
    • Recombinant Human VEGF 165A



Our Abpromise guarantee covers the use of ab106580 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 22 kDa (predicted molecular weight: 22 kDa).
ELISA 1/10000.


  • FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
  • Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
  • Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
  • Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
  • Information by UniProt
  • Database links
  • Alternative names
    • glioma-derived endothelial cell mitogen antibody
    • MGC70609 antibody
    • MVCD1 antibody
    • Vascular endothelial growth factor A antibody
    • Vascular Endothelial Growth Factor antibody
    • Vascular permeability factor antibody
    • VEGF antibody
    • VEGF-A antibody
    • VEGF165 antibody
    • Vegfa antibody
    • VEGFA_HUMAN antibody
    • VPF antibody
    see all

Anti-VEGF 165A antibody images

  • Anti-VEGF 165A antibody (ab106580) at 1/1000 dilution + Recombinant Human VEGF 165A

    Peroxidase conjugated anti-Rabbit IgG at 1/40000 dilution

    Predicted band size : 22 kDa

References for Anti-VEGF 165A antibody (ab106580)

ab106580 has not yet been referenced specifically in any publications.

Product Wall

I can confirm that the immunogen is full length recombinant human VEGF-165 protein and ab106580 is a polyclonal antibody. We therefore assume that there are multiple binding sites. Unfortunately with polyclonal antibodies this can not be further mapped...

Read More